Syndax Unveils Promising Revuforj and Niktimvo Data at ASH 2025
Syndax Pharmaceuticals Inc. announced that 23 abstracts, including six oral presentations, featuring data on Revuforj® and Niktimvo™ have been accepted for the 67th ASH Annual Meeting in December 2025. The presentations will cover new data on Revuforj's efficacy in acute leukemia and long-term safety for Niktimvo in chronic GVHD. Results are scheduled for future release at the meeting.
Syndax Pharmaceuticals Inc. announced that 23 abstracts, including six oral presentations, featuring data on Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) have been accepted for presentation at the 67th American Society of Hematology (ASH) Annual Meeting, scheduled to take place in Orlando, Florida, from December 6-9, 2025. The presentations will include new frontline datasets on the tolerability and efficacy of Revuforj in combination with standard of care therapies for acute leukemia, as well as real-world evidence and post-transplant usage. Additionally, long-term safety and duration data for Niktimvo in recurrent or refractory chronic GVHD, and interim safety results from a Phase 2 trial of axatilimab with ruxolitinib in newly diagnosed chronic GVHD will be presented. The results have not yet been presented and are scheduled for future release at the ASH meeting. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Syndax Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9567280-en) on November 03, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
